Sponsored by ?

This article was paid for by a contributing third party.More Information.

Tackling buy-side OTC derivatives challenges: Regulations, risks and collateral management

Sponsored webinar: Calypso


  • Glenn Barry, managing director, derivatives and quantitative strategies, Sun Life Investment Management
  • Lisa Cavallari, director of fixed income derivatives and commodities, Russell Investments
  • Sylvain Privat, head of product management, investment management solutions, Calypso Technology
  • James Wallin, senior vice-president, AllianceBernstein
  • Moderator: Duncan Wood, editor-in-chief, Risk.net

Despite a steady increase in the use of derivatives among investment managers, research from Asia Risk indicates many firms are still facing serious regulatory and technology challenges.

In a recent Asia Risk survey, an overwhelming 80% of the respondents said that over-the-counter derivatives were a concern from both a risk management and operations perspective. In addition, 60% say they do not have real-time, intra-day access to their collateral inventory, while 70% are not able to optimise their collateral on a pre-trade basis.

  • LinkedIn  
  • Save this article
  • Print this page  

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: